Balyasny Asset Management’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$21.6M Buy
23,500
+1,400
+6% +$1.42M 0.03% 661
2025
Q4
$23.8M Sell
22,100
-5,400
-20% -$5.16M 0.03% 630
2025
Q3
$21M Buy
27,500
+11,000
+67% +$8.19M 0.03% 695
2025
Q2
$12.9M Sell
16,500
-27,000
-62% -$21M 0.02% 851
2025
Q1
$35.9M Hold
43,500
0.06% 392
2024
Q4
$33.6M Buy
43,500
+26,600
+157% +$22M 0.05% 456
2024
Q3
$15M Buy
16,900
+5,500
+48% +$4.94M 0.02% 764
2024
Q2
$10.3M Buy
11,400
+1,300
+13% +$1.04M 0.02% 871
2024
Q1
$7.86M Sell
10,100
-58,700
-85% -$41.8M 0.01% 1038
2023
Q4
$40.1M Sell
68,800
-304,400
-82% -$178M 0.08% 330
2023
Q3
$200M Buy
373,200
+152,200
+69% +$78.4M 0.41% 33
2023
Q2
$104M Buy
221,000
+219,800
+18,317% +$92.2M 0.23% 97
2023
Q1
$412K Buy
+1,200
New +$405K ﹤0.01% 2005
2022
Q3
Sell
-5,000
Closed -$1.62M 3080
2022
Q2
$1.62M Buy
+5,000
New +$1.5M 0.01% 1521
2021
Q3
Sell
-133,800
Closed -$30.7M 2208
2021
Q2
$30.7M Buy
+133,800
New +$26.9M 0.15% 179
2019
Q4
Sell
-100,000
Closed -$11.2M 1345
2019
Q3
$11.2M Buy
+100,000
New +$11.1M 0.08% 369
2019
Q2
Sell
-54,000
Closed -$7.01M 1623
2019
Q1
$7.01M Buy
+54,000
New +$6.57M 0.05% 484
2018
Q4
Sell
-568,000
Closed -$60.4M 1582
2018
Q3
$60.4M Buy
+568,000
New +$56.8M 0.27% 80
2015
Q3
Sell
-425,000
Closed -$35.5M 1281
2015
Q2
$35.5M Buy
+425,000
New +$32.4M 0.22% 116

Other funds holding LLY

Balyasny Asset Management's LLY Position: Q1 2026 in Review

Balyasny Asset Management reduced its Eli Lilly (LLY) stake by 86% in Q1 2026, selling an estimated $111M and leaving 17,835 shares worth $16.4M. The position accounts for 0.02% of the portfolio, ranked #778.

Balyasny Asset Management first reported a position in LLY in Q4 2014 and has held it in 39 quarters since. The position peaked at $390M in Q2 2025. 4,353 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Balyasny Asset Management held 17,835 shares of Eli Lilly worth $16.4M as of Q1 2026.
  • Balyasny Asset Management sold 109,173 Eli Lilly shares in Q1 2026, an estimated $111M.
  • Eli Lilly made up 0.02% of Balyasny Asset Management's portfolio in Q1 2026, its #778 holding.
  • Balyasny Asset Management first reported a position in Eli Lilly in Q4 2014 and has held it in 39 quarters since.
  • Balyasny Asset Management's Eli Lilly position peaked at $390M in Q2 2025.
  • 4,353 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.